NASDAQ:EGRX - Eagle Pharmaceuticals Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$83.39 -0.47 (-0.56 %)
(As of 07/22/2018 08:24 AM ET)
Previous Close$83.39
Today's Range$83.05 - $85.66
52-Week Range$45.05 - $85.66
Volume156,060 shs
Average Volume200,379 shs
Market Capitalization$1.24 billion
P/E Ratio34.60
Dividend YieldN/A
Beta1.47
Eagle Pharmaceuticals logoEagle Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing injectable products primarily in the critical care and oncology areas in the United States. The company offers argatroban for heparin-induced thrombocytopenia; Ryanodex for malignant hyperthermia; non-alcohol docetaxel injection, a chemotherapeutic agent for breast, non-small cell lung, prostate, head, and neck cancers/gastric adenocarcinoma; and Bendeka for chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin's lymphoma (NHL). Its product candidates includes include EP-3101, (bendamustine ready-to-dilute) for CLL and indolent B-cell NHL; EP-4104, a dantrolene sodium for exertional heat stroke; EGL-4104-C-1702, dantrolene sodium for drug induced hyperthermia; EP-5101 (pemetrexed) for lung cancer and mesothelioma; and EGL-5385-C-1701 (fulvestrant) for breast cancer. Eagle Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Woodcliff Lake, New Jersey.

Receive EGRX News and Ratings via Email

Sign-up to receive the latest news and ratings for EGRX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:EGRX
CUSIPN/A
Phone201-326-5300

Debt

Debt-to-Equity Ratio0.23
Current Ratio5.87
Quick Ratio5.66

Price-To-Earnings

Trailing P/E Ratio34.60
Forward P/E Ratio33.36
P/E GrowthN/A

Sales & Book Value

Annual Sales$236.71 million
Price / Sales5.23
Cash Flow$3.8589 per share
Price / Cash21.61
Book Value$12.01 per share
Price / Book6.94

Profitability

EPS (Most Recent Fiscal Year)$3.37
Net Income$51.94 million
Net Margins15.32%
Return on Equity21.89%
Return on Assets15.09%

Miscellaneous

Employees108
Outstanding Shares14,840,000
Market Cap$1,237.09

Eagle Pharmaceuticals (NASDAQ:EGRX) Frequently Asked Questions

What is Eagle Pharmaceuticals' stock symbol?

Eagle Pharmaceuticals trades on the NASDAQ under the ticker symbol "EGRX."

How will Eagle Pharmaceuticals' stock buyback program work?

Eagle Pharmaceuticals announced that its board has approved a share repurchase plan on Thursday, August 10th 2017, which authorizes the company to repurchase $100,000,000.00 in shares, according to EventVestor. This repurchase authorization authorizes the company to repurchase up to 13.3% of its shares through open market purchases. Shares repurchase plans are often a sign that the company's management believes its stock is undervalued.

How were Eagle Pharmaceuticals' earnings last quarter?

Eagle Pharmaceuticals Inc (NASDAQ:EGRX) posted its earnings results on Thursday, May, 10th. The specialty pharmaceutical company reported $0.53 earnings per share for the quarter, missing the Zacks' consensus estimate of $0.68 by $0.15. The specialty pharmaceutical company had revenue of $46.60 million for the quarter, compared to analysts' expectations of $48.88 million. Eagle Pharmaceuticals had a return on equity of 21.89% and a net margin of 15.32%. The company's revenue was down 39.3% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $1.42 earnings per share. View Eagle Pharmaceuticals' Earnings History.

What price target have analysts set for EGRX?

4 brokerages have issued 1 year price objectives for Eagle Pharmaceuticals' stock. Their forecasts range from $54.00 to $81.00. On average, they anticipate Eagle Pharmaceuticals' share price to reach $71.25 in the next twelve months. This suggests that the stock has a possible downside of 14.6%. View Analyst Ratings for Eagle Pharmaceuticals.

What is the consensus analysts' recommendation for Eagle Pharmaceuticals?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Eagle Pharmaceuticals in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy."

What are Wall Street analysts saying about Eagle Pharmaceuticals stock?

Here are some recent quotes from research analysts about Eagle Pharmaceuticals stock:
  • 1. According to Zacks Investment Research, "Eagle Pharmaceuticals, Inc. is a specialty pharmaceutical company. It focuses on developing and commercializing injectable products primarily in the critical care and oncology areas in the United States. The Company markets EP-1101 to treat heparin-induced thrombocytopenia. It develops EP-3101, EP-3102, Ryanodex and EP-4104. Eagle Pharmaceuticals, Inc. is based in Woodcliff Lake, New Jersey. " (7/11/2018)
  • 2. Mizuho analysts commented, "We don’t yet have this product in our model, and don’t expect it to be a meaningful revenue generator because Treanda powder currently has minimal market share. Big bag" may provide insurance if Eagle fails to bar Treanda generics from the market via its Orphan Drug litigation, in our view. The Fulvestrant clinical trial is fully enrolled, and data are expected in the fall. Additionally, the FDA accepted Eagle’s Vasostrict ANDA, which Endo indicated would be subject to the full litigation pathway. We have no estimates for the Ryanodex program for nerve agent exposure and note that Eagle did not provide an update on its drug- induced hyperthermia program, which we believe could get dropped. We summarize 1Q:18 performance below and reiterate our Underperform rating." (5/10/2018)

Who are some of Eagle Pharmaceuticals' key competitors?

Who are Eagle Pharmaceuticals' key executives?

Eagle Pharmaceuticals' management team includes the folowing people:
  • Mr. Scott L. Tarriff, CEO & Director (Age 58)
  • Mr. David M. Pernock, Pres & Chief Commercial Officer (Age 65)
  • Mr. Pete A. Meyers, Chief Financial Officer (Age 48)
  • Dr. Adrian Hepner, Exec. VP & Chief Medical Officer (Age 57)
  • Mr. Daniel O'Connor, Exec. VP of Biologics and Corp. Devel. (Age 38)

Has Eagle Pharmaceuticals been receiving favorable news coverage?

News headlines about EGRX stock have trended somewhat positive this week, Accern Sentiment reports. The research group rates the sentiment of press coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Eagle Pharmaceuticals earned a news sentiment score of 0.15 on Accern's scale. They also gave news stories about the specialty pharmaceutical company an impact score of 45.89 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company's share price in the near term.

Who are Eagle Pharmaceuticals' major shareholders?

Eagle Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Fisher Asset Management LLC (0.14%), Hartford Investment Management Co. (0.05%), Louisiana State Employees Retirement System (0.02%) and Municipal Employees Retirement System of Michigan (0.02%). Company insiders that own Eagle Pharmaceuticals stock include David Pernock, Douglas L Braunstein, Pete A Meyers, Proquest Investments Iv, LP, Richard A Edlin, Sander A Flaum, Sander A Flaum, Steven B Ratoff and Steven L Krill. View Institutional Ownership Trends for Eagle Pharmaceuticals.

Which institutional investors are selling Eagle Pharmaceuticals stock?

EGRX stock was sold by a variety of institutional investors in the last quarter, including Fisher Asset Management LLC and Municipal Employees Retirement System of Michigan. View Insider Buying and Selling for Eagle Pharmaceuticals.

Which institutional investors are buying Eagle Pharmaceuticals stock?

EGRX stock was purchased by a variety of institutional investors in the last quarter, including Hartford Investment Management Co. and Louisiana State Employees Retirement System. Company insiders that have bought Eagle Pharmaceuticals stock in the last two years include David Pernock, Douglas L Braunstein, Pete A Meyers and Richard A Edlin. View Insider Buying and Selling for Eagle Pharmaceuticals.

How do I buy shares of Eagle Pharmaceuticals?

Shares of EGRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Eagle Pharmaceuticals' stock price today?

One share of EGRX stock can currently be purchased for approximately $83.39.

How big of a company is Eagle Pharmaceuticals?

Eagle Pharmaceuticals has a market capitalization of $1.24 billion and generates $236.71 million in revenue each year. The specialty pharmaceutical company earns $51.94 million in net income (profit) each year or $3.37 on an earnings per share basis. Eagle Pharmaceuticals employs 108 workers across the globe.

How can I contact Eagle Pharmaceuticals?

Eagle Pharmaceuticals' mailing address is 50 TICE BOULEVARD SUITE 315, WOODCLIFF LAKE NJ, 07677. The specialty pharmaceutical company can be reached via phone at 201-326-5300 or via email at [email protected]


MarketBeat Community Rating for Eagle Pharmaceuticals (NASDAQ EGRX)

Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  312 (Vote Outperform)
Underperform Votes:  176 (Vote Underperform)
Total Votes:  488
MarketBeat's community ratings are surveys of what our community members think about Eagle Pharmaceuticals and other stocks. Vote "Outperform" if you believe EGRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EGRX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 7/22/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.